Literature DB >> 9820878

Streptozotocin- and alloxan-induced diabetes modifies total plasma and lipoprotein lipid concentration and composition without altering cholesteryl ester transfer activity.

K M Wasan1, S P Ng, W Wong, B B Rodrigues.   

Abstract

The objectives of this study were to determine the total plasma and lipoprotein lipid concentration and composition and cholesteryl ester transfer activity in two diabetic animal models (alloxan-induced diabetes in rabbits and streptozotocin-induced diabetes in rats). Furthermore, we wanted to determine if the severity of diabetes influences lipoprotein lipid profiles and cholesteryl ester transfer activity. Rats and rabbits were randomly divided into non-diabetic and diabetic groups. Rats were administered either 55 mg/kg or 100 mg/kg of streptozotocin intravenously through the tail vein, while rabbits were administered 100 mg/kg or 200 mg/kg of alloxan intravenously through the marginal ear vein under light anesthesia. Hyperglycaemia was tested for at 48 hr following the doses. Total and lipoprotein cholesterol and triglyceride concentrations using enzymatic kits and cholesteryl ester transfer activity from low-density lipoproteins to high-density lipoproteins using 3H-cholesteryl ester incorporated into low-density lipoproteins were determined. Elevations in both total and lipoprotein cholesterol and triglyceride concentrations and alterations in lipoprotein lipid composition are observed following the onset of drug-induced diabetes in rats and rabbits compared to non-diabetics. However, these findings were observed only in animals administered the higher streptozotocin and alloxan dose. Furthermore, cholesteryl ester transfer from low-density lipoproteins to high-density lipoproteins is not significantly different in drug-induced diabetic compared to non-diabetic rats and rabbits, regardless of which streptozotocin and alloxan dose was used. These findings suggest that difference in lipoprotein lipid concentration and composition as a result of drug-induced diabetes is independent of cholesteryl ester transfer activity in both rats and rabbits. Furthermore, diabetic severity may influence lipoprotein metabolism in these animal models.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9820878     DOI: 10.1111/j.1600-0773.1998.tb01464.x

Source DB:  PubMed          Journal:  Pharmacol Toxicol        ISSN: 0901-9928


  6 in total

1.  Therapeutic effects of stem cell on hyperglycemia, hyperlipidemia, and oxidative stress in alloxan-treated rats.

Authors:  Walid Hamdy El-Tantawy; Ekram Nemr Abd Al Haleem
Journal:  Mol Cell Biochem       Date:  2014-03-07       Impact factor: 3.396

2.  Adverse cardiac responses to alpha-lipoic acid in a rat-diabetic model: possible mechanisms?

Authors:  Nouf M Al-Rasheed; Nawal M Al-Rasheed; Hala A Attia; Iman H Hasan; Maha Al-Amin; Hanaa Al-Ajmi; Raeesa A Mohamad
Journal:  J Physiol Biochem       Date:  2013-04-18       Impact factor: 4.158

3.  Antidiabetic Potency, Antioxidant Effects, and Mode of Actions of Citrus reticulata Fruit Peel Hydroethanolic Extract, Hesperidin, and Quercetin in Nicotinamide/Streptozotocin-Induced Wistar Diabetic Rats.

Authors:  Alaa M Ali; Mohamed Abdel Gabbar; Sanaa M Abdel-Twab; Eman M Fahmy; Hossam Ebaid; Ibrahim M Alhazza; Osama M Ahmed
Journal:  Oxid Med Cell Longev       Date:  2020-06-20       Impact factor: 6.543

4.  Effects of coenzyme Q10 and α-lipoic acid supplementation in fructose fed rats.

Authors:  Serhat Ozdoğan; Dilara Kaman; Bengü Çobanoğlu Simşek
Journal:  J Clin Biochem Nutr       Date:  2011-09-03       Impact factor: 3.114

5.  Amelioration of Hyperglycaemia, Oxidative Stress and Dyslipidaemia in Alloxan-Induced Diabetic Wistar Rats Treated with Probiotic and Vitamin C.

Authors:  Tagang Aluwong; Joseph O Ayo; Alkali Kpukple; Olusola Olalekan Oladipo
Journal:  Nutrients       Date:  2016-05-05       Impact factor: 5.717

6.  Streptozotocin, type I diabetes severity and bone.

Authors:  Katherine Motyl; Laura R McCabe
Journal:  Biol Proced Online       Date:  2009-03-06       Impact factor: 3.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.